Abstract:Molecular testing has become state of the art in the diagnostic work‐up of myeloid neoplasms and molecular features have been incorporated into their classification, together with clinicopathological features. Molecular patterns can inherently help to classify overlapping entities if considered within a framework of haematological presentations. Myeloid neoplasms include myeloproliferative and myelodysplastic neoplasms and acute myeloid leukaemia. Historically, these diseases have been diagnosed based on clinicopathological features with sometimes arbitrary thresholds that have persisted even as molecular features were gradually incorporated into their classification. As such, although current diagnostic approaches can classify the majority of myeloid neoplasms accurately using a combination of molecular and clinicopathological features, some areas of overlap persist and occasionally pose diagnostic challenges. These include overlap across BCR::ABL1‐negative myeloproliferative neoplasms; between clonal cytopenia of undetermined significance and myelodysplastic neoplasms; myelodysplastic/myeloproliferative neoplasms; and, detection of KIT mutations in myeloid neoplasms other than mastocytosis, raising the prospect of systemic mastocytosis. Molecular testing has become state of the art in the diagnostic work‐up of myeloid neoplasms, and molecular patterns can inherently help to classify overlapping entities if considered within a framework of haematological presentations. For future development, molecular testing will likely include whole genome and transcriptome sequencing, and primarily molecular classifications of myeloid neoplasms have already been suggested. As such, genetically defined groups should still constitute the basis for our understanding of disease development from early onset to progression, while clinicopathological features could then be used to describe the stage of the disease rather than the specific type of myeloid neoplasm.

Molecular techniques in haematopathology: what and how?

Progress in the application of FISH for the molecular characterization of lymphomas

Cytogenetics in the management of hematological malignancies: an overview of alternative technologies for cytogenetic characterization

Molecular techniques in cytopathology practice

Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use

Novel precision medicine approaches and treatment strategies in hematological malignancies

Multiplex technologies for the assessment of minimal residual disease and low-level mutation detection in leukaemia: mass spectrometry versus next-generation sequencing

The landscape of cytogenetic and molecular genetic methods in diagnostics for hematologic neoplasia

Genomic profiling for clinical decision making in lymphoid neoplasms

Can molecular patterns help to classify overlapping entities in myeloid neoplasms?

Molecular testing in cytology

Innovative Molecular Testing Strategies for Adjunctive Investigations in Hemostasis and Thrombosis

Molecular MRD Assessment in Acute Myeloid Leukemias

Phenotypic clues that predict underlying cytogenetic/genetic abnormalities in myeloid malignancies: A contemporary review

Morphology and multiparameter flow cytometry combined for integrated lymphoma diagnosis on small volume samples: possibilities and limitations

Predictive and prognostic molecular biomarkers in lymphomas

[Molecular pathological analysis through the ages]

Liquid biopsy in lymphoma: Molecular methods and clinical applications

The impact of next-generation sequencing for diagnosis and disease understanding of myeloid malignancies

Precision diagnostics in chronic lymphocytic leukemia: Past, present and future

Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia